3D Hepatocyte Spheroid Culture for Long-Term Proliferation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing 2D and conventional 3D culture systems for primary human hepatocytes fail to maintain hepatocyte-specific functions and do not support proliferation, making them unsuitable for long-term in vitro studies and therapeutic applications.

Innovation Solution

A method involving culturing primary human hepatocytes in a non-adherent vessel, followed by embedding them in a collagen or gelatin matrix, particularly GelMa, to form spheroids with a hollow lumen, which supports proliferation and maintains hepatocyte phenotype.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional two-dimensional monolayer culture is used, then ease of operation is maintained, but hepatocyte function deteriorates and culture duration is limited

Engineering Contradiction:
Improvehepatocyte functionVSAvoidculture system complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent transitions from conventional two-dimensional monolayer culture to three-dimensional spheroid culture. Hepatocytes are cultured in hanging drop format where cells aggregate to form spheroids, enabling them to maintain functional characteristics such as albumin secretion and cytochrome P450 activity for extended periods while preserving ease of operation through standardized protocols

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

2Productivity

If primary hepatocytes are cultured beyond 72 hours, then productivity increases, but cell function deteriorates due to contact inhibition and functional loss

Engineering Contradiction:
Improveculture durationVSAvoidcell function
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

By forming three-dimensional spheroids, hepatocytes escape contact inhibition that occurs in monolayer culture. The spheroid architecture allows cells to maintain functional morphology and metabolic activity for over 72 hours, enabling extended culture duration while preserving cell function for downstream applications

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Solution Approach 2:

The patent modifies culture parameters including using serum-free media with specific supplements (insulin, transferrin, selenium), controlling drop volume (50-200 µL), and maintaining specific cell densities to optimize spheroid formation and maintain hepatocyte functionality during extended culture periods

Inventive Principle:
Principle #35Parameter changes

3Productivity

If hepatocytes are passaged or subcultured, then productivity and cell availability increase, but cell function and viability are significantly reduced

Engineering Contradiction:
Improvecell availabilityVSAvoidcell viability
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent creates self-renewing hepatocyte colonies through spheroid formation. Each spheroid acts as a self-contained unit that can be expanded by generating multiple colonies from a single spheroid without requiring traditional passaging. This copying approach maintains cell viability and function while increasing cell availability for experimental use

Inventive Principle:
Principle #26Copying

Data Source

PatentEP3794107B1Method of culturing proliferative hepatocytes
Publication Date: 2026.04.29 ECOLE DES HAUTES ETUD & SANTE PUBLIQUE EHESP
  • EP3794107B1 patent drawingFigure 1A~2B
  • EP3794107B1 patent drawingFigure 2C~2H
  • EP3794107B1 patent drawingFigure 3A~3B

AI summary

The present invention relates to a method of culturing animal cells, preferably primary hepatocytes, comprising a first step of culturing the animal cells in non-adherent culture vessel, preferably a low or ultra-low attachment culture vessel, a second step of embedding the animal cells in a collagen matrix or in a gelatin matrix, and a third step of culturing the animal cells embedded in the collagen matrix or in the gelatin matrix, thereby obtaining 3D animal cell structures comprising proliferative animal cells, preferably spheroids comprising proliferative primary hepatocytes. The invention also relates to a spheroid comprising proliferative primary hepatocytes and the uses thereof for engineering an artificial liver model or an artificial liver organ, and for assessing in vitro the liver toxicity, genotoxicity and/or the effects of a drug or a compound.